Blood Banking (Safety)

Heat Treatment Step Added for Dual Viral Inactivation of Factor VIII Product

Published in Blood Weekly, March 31st, 1997

Alpha Therapeutic Corp., Los Angeles, California, has obtained clearance from the U.S. Food and Drug Administration (FDA) to include the addition of a heat treatment step for the solvent detergent treated Antihemophilic Factor (AHF) product.

AHF was developed in an ongoing effort to provide an added measure of viral safety for plasma derived biopharmaceutical products. Alphanate Antihemophilic Factor (Human), Solvent Detergent/Heat Treated is the first AHF product in the U.S. that incorporates solvent detergent and heat treatment methods of viral inactivation.

The first step incorporated by Alpha solvent detergent treatment inactivates...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1997-03-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry